drugset / Trial / NCT05297201
Efficacy, Safety and Pharmacokinetic Study of CPL500036 in Patients with Levodopa Induced Dyskinesia
Phase 2
Completed
105 enrolled
Celon Pharma SA
National Center for Research and Development, Poland · collab
NaParallel-groupDouble-blindTreatment
Summary
The aim of the study is to determine potential anti-dyskinetic properties of CPL500036 (PDE10A inhibitor) in Parkinson disease patients suffering from levodopa Induced dyskinesia. The study is to determine the efficacy and dose response of two CPL500036 doses, compared with placebo.
Timeline
- Start
- 2021-11-02
- Primary completion
- 2025-01-13
- Completion
- 2025-01-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CPL500036 | Unknown | 20 mg | Oral |
| Subject | CPL500036 | Unknown | 40 mg | Oral |